Neurocrine Biosciences, Inc.’s recently made public that its Chief Corp. Affairs Officer Boyer David W. unloaded Company’s shares for reported $0.42 million on Sep 13 ’24. In the deal valued at $121.88 per share,3,461 shares were sold. As a result of this transaction, Boyer David W. now holds 1,672 shares worth roughly $0.19 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, DAVID WARREN BOYER bought 4,756 shares, generating $576,808 in total proceeds.
Before that, RASTETTER WILLIAM H sold 14,250 shares. Neurocrine Biosciences, Inc. shares valued at $2,090,332 were divested by the Director at a price of $146.69 per share. As a result of the transaction, RASTETTER WILLIAM H now holds 37,491 shares, worth roughly $4.2 million.
Piper Sandler upgraded its Neurocrine Biosciences, Inc. [NBIX] rating to an Overweight from a a Neutral in a research note published on August 29, 2024; the price target was increased to $159 from $131. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in late April from “an Equal weight” to “an Overweight”. Deutsche Bank started covering the stock on December 12, 2023. It rated NBIX as “a Buy”.
Price Performance Review of NBIX
On Monday, Neurocrine Biosciences, Inc. [NASDAQ:NBIX] saw its stock fall -1.61% to $112.16. Over the last five days, the stock has lost -2.66%. Neurocrine Biosciences, Inc. shares have fallen nearly -14.88% since the year began. Nevertheless, the stocks have fallen -2.72% over the past one year. While a 52-week high of $157.98 was reached on 08/01/24, a 52-week low of $103.63 was recorded on 10/03/24. SMA at 50 days reached $131.99, while 200 days put it at $136.04.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 111.32, which if violated will result in even more drops to 110.49. On the upside, there is a resistance level at 113.54. A further resistance level may holdings at 114.93. The Relative Strength Index (RSI) on the 14-day chart is 29.46, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.02, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.35%. Stochastics %K at 13.76% indicates the stock is a buying.
How much short interest is there in Neurocrine Biosciences, Inc.?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc. stocks on 2024-09-13, dropping by 57556.0 shares to a total of 2.23 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 2.29 million shares. There was a decline of -2.58%, which implies that there is a negative sentiment for the stock.
